Introduction
============

As people age, the incidence of age-related health diseases such as cerebral infarction, cardiovascular disease, and diabetes increases. Besides these primary diseases, aging is also associated with attenuation of the immune system.^([@B1],[@B2])^ While medical care for primary diseases is important, support for the immune system is also required in the elderly patients. Because many of them already take a variety of medicines for their primary diseases, most would prefer not to take more.

Nutritional supplementation with amino acids and vitamins has been shown to affect immune variables. Glutamine and arginine are thought to be good candidates for immune system support.^([@B3],[@B4])^ Glutamine is the most abundant free amino acid in blood and constitutes more than 50% of the amino acid pool in human skeletal muscle. Macrophages and lymphocytes contributing to the immune system require glutamine as a fuel.^([@B5])^ It has been observed that glutamine causes neutrophils to increase their phagocytic activity in a dose-dependent manner.^([@B6])^ Glutamine is also utilized as a major fuel source by intestinal mucosal cells and influences the gut-associated immune system.^([@B7]--[@B9])^ In an *in vitro* study, glutamine decreased the tumor necrosis factor α-mediated bacterial translocation in enterocytes.^([@B10])^ Another *in vivo* study demonstrated that glutamine-supplemented rat group with an obstructed terminal ileum had fewer positive cultures in blood after injection of *E coli* into the ileal lumen.^([@B11])^ Although glutamine is not an essential amino acid, it is considered to be a conditionally essential amino acid because its plasma levels decrease sharply when people are critically ill.^([@B12],[@B13])^ Arginine is also a nonessential amino acid, but has been reported to become conditionally essential in the critically ill.^([@B14],[@B15])^ It has been observed that arginine prevents thymic involution after surgery and increases the number of lymphocytes. Therefore, it acts as a potent modulator of immune function.^([@B16]--[@B18])^ Several studies have demonstrated that arginine intake improves T-cell activity, neutrophil chemotaxis, and natural killer (NK) cytotoxicity.^([@B4],[@B19]--[@B21])^ Moreover, multivitamin, including vitamin C and E, is known to improve immunity.^([@B22])^ It has been observed that various types of diseases such as cancer and hypertension produce reactive oxygen species that impair immune function.^([@B23]--[@B25])^ Therefore, antioxidant effects of vitamins are thought to be beneficial for maintenance of the immune function.

In addition to attenuation of immune function, involuntary loss of muscle mass with aging (sarcopenia) is also a serious problem for maintaining a quality of life. Although resistance exercise programs are recommended for the elderly to prevent sarcopenia, it is difficult for them to engage in these because many of them suffer from multiple diseases. Therefore, nutritional approaches to prevent sarcopenia have been evaluated. It has been observed that leucine, an essential amino acid, activates intracellular kinases linked to the translation of proteins such as those associated with the mammalian target of rapamycin signaling pathway, which includes the 70-kDa ribosomal protein S6 kinase and eukaryotic initiation factor 4E-binding protein 1, leading to stimulation of muscle protein synthesis.^([@B26]--[@B29])^ It has been observed that supplementation with a high proportion of leucine in an oral mixture of essential amino acids resulted in an additional 0.008% per hour increase in the postprandial muscle protein synthetic rate for 2.5 h in healthy older men.^([@B30])^

Based on these studies, we hypothesized that supplementation with a mixture of glutamine, arginine, leucine, and vitamins may have beneficial health effects on the elderly in poor health.

Methods
=======

Bedridden inpatients
--------------------

Thirteen bedridden inpatients (7 males, 6 females; mean age, 81.8 ± 8 years) participated in this study. The hospitalized duration of the bedridden inpatients was 16.4 ± 7.6 months. All participants were Japanese; their health status and the prescription drugs they were taking are summarized in Table [1](#T1){ref-type="table"}. Eleven of 13 bedridden inpatients underwent percutaneous endoscopic gastrostomy (PEG). Three bedridden inpatients dropped out for the following reasons: 1 (female) had gastritis, 1 (male) had pneumonia, and 1 (male) was moved to another hospital. Doctors confirmed that the causes of discontinuance were not attributed to this trial.

Outpatients
-----------

Eleven outpatients (7 males, 4 females; mean age, 74 ± 12 years; body mass index, 21.0 ± 3.7) from the Sansei Hospital (Hyogo Prefecture, Japan) participated in this study. The duration of ambulatory visits to the hospital for the outpatients was 117.6 ± 64.0 months. All participants were Japanese; their health status and the prescription drugs they were taking are summarized in Table [1](#T1){ref-type="table"}. Two male outpatients dropped out, 1 because of hospitalization (worsening of prostate cancer) and 1 because of a bone fracture. Doctors confirmed that the causes of discontinuance were not attributed to this trial.

Experimental procedures
-----------------------

Administering a placebo to patients as a control group was not agreeable to them and their families. Therefore, in this study we could not set the placebo group. All experimental procedures were performed in accordance with the Declaration of Helsinki. All participants and their families were informed about the experimental procedures and purpose of the study, and they gave written informed consent prior to participation. The ethics committee of the Sansei Hospital approved this study. The duration of this study was 8 weeks.

Diet and supplementation programs for the bedridden inpatients
--------------------------------------------------------------

The bedridden inpatient participants were administered a liquid diet (Isocal 2K, Nestle Nutrition Co., Tokyo, Japan) twice (morning and evening) daily. The composition of the diet is presented in Table [2](#T2){ref-type="table"}. The amount of the liquid diet was determined by medical doctors according to the participants' health conditions (mean total calorie, 1147 ± 334 kcal/day; mean protein intake, 39.0 ± 11.3 g/day). A powder containing amino acids and vitamins was mixed in the diet. To avoid malabsorption, the powder was mixed with each of the two daily doses of the liquid diet. The composition of the supplementation is presented in Table [3](#T3){ref-type="table"}. This composition was based on our previous studies in which it improved health conditions in young male athletes.^([@B31],[@B32])^

Diet and supplementation programs for the outpatients
-----------------------------------------------------

The same amino acid and vitamin supplementation as the inpatients was administered to the outpatients with water twice daily, immediately after dinner and before sleeping. Because they already took a variety of medicines with water for their primary diseases from morning to evening, to avoid satiety, most of them preferred to take the supplementation at evening and before sleep. When the supplementation was administered to the outpatients, they recorded it on a check sheet. The researchers subsequently confirmed the compliance of their supplementation programs. The daily diet of the outpatients was almost the same throughout the trial period except for the additional amino acid and vitamin supplementation. Their habitual nutrient intake was analyzed using food-frequency questionnaires.^([@B33])^

Anthropometric evaluation
-------------------------

Initially, the outpatient participants were subjected to anthropometric evaluation. The anthropometric evaluation included height, body weight, and body composition comprising fat and lean body mass. Body composition was evaluated by bioimpedance (X-Scan plus, Owa Medical Co., Fukuoka, Japan). This system applies to a constant current of 100 µA at 1, 5, 50, 250, and 550 kHz, and 280 µA at 1000 kHz thorough the body. Subjects restrained from vigorous exercise and alcohol intake during 24 h, preceding the measurements. The room temperature was kept at 23°C. Bioimpedance measurements of whole body were theoretically based on a previous study.^([@B34])^ The participants did not agree to using computed tomography and dual energy X-ray absorptiometry to evaluate body composition owing to concerns of radiation exposure. Anthropometric evaluations were not performed for bedridden inpatients because they faced difficulty in standing.

Blood sampling and measurement of body temperature
--------------------------------------------------

Fasting venous blood samples were collected from each subject at least 24 h before the trial (baseline), on the last day of the 4-week (mid-point) period and on the last day of the 8-week (post-point) period. The body temperature of bedridden inpatients was measured daily. The number of days on which had a fever above 37°C was counted and the frequency (febrile frequency, the number of days for which body temperature was more than 37°C/the number of days per month ×100) was compared with that of control inpatients (*n* = 11) who did not participate in this study but were hospitalized in the same room as the participating inpatients. The control inpatients underwent PEG and were administered the same liquid diet as the inpatient participants (mean total calorie, 1140 ± 134 kcal/day; mean protein intake, 38.8 ± 5.0 g/day).

Blood analyses
--------------

Complete blood count and hematocrit were analyzed using an automated hematology analyzer (Coulter Electronics, Hialeah, FL). Concentrations of total plasma proteins, serum albumin, blood urea nitrogen, serum creatinine, and serum amylase activity were determined by routine methods. Serum aspartate aminotransferase, alanine aminotransferase, leucine aminopeptidase, cholinesterase, gamma-glutamyltranspeptidase, and total bilirubin levels were used as liver function markers and measured by routine methods. C-reactive protein (CRP) level was used as an inflammation marker and measured using a latex agglutination immunoassay (EIKEN Chemical, Co. Ltd., Tokyo, Japan). To measure the *in vitro* tumoricidal activity of NK cells, cytotoxicity was measured by determining the amount of ^51^Cr released from target cells at an effector : target (E/T) ratio of 20:1.^([@B35])^ Blood samples were centrifuged at 1500 × *g* (20°C) for 20 min and then 200 µL of prepared lymphocyte cells (1 × 10^6^ cells/ml) and 10 µL of prepared K562 human chronic myelogenous leukemia cells (1 × 10^6^ cells/ml) labeled with ^51^Cr were added to a plate. The plate was then incubated for 3.5 h at 37°C in an atmosphere of 5% CO~2~. Following incubation, the activity of NK cells was counted using a scintillation counter (Perkin Elmer Japan Co. Ltd., Kanagawa, Japan).

Statistical analysis
--------------------

The data of dropped out participants were excluded from the data analyses. All data were expressed as mean ± SD. The differences between the variables were examined by one-way analysis of variance (ANOVA), followed by Fisher's protected least significant difference post-hoc test. Body temperature data were examined using 2 (condition) ×2 (time of measurement) ANOVA for interaction and main effects. When a statistical significance was obtained, Student's *t* test was used to compare the 2 groups and for comparisons within the same group. Statistical significance was accepted at the *p* = 0.05 level.

Results
=======

The outpatients mean habitual nutrient intake was 34.1 ± 3.8 kcal/kg/day including 1.27 ± 0.32 g protein/kg/day. Body weight and body composition in the outpatients did not change throughout the trial (Fig. [1](#F1){ref-type="fig"}a). At mid-point, NK cell activity in the bedridden inpatients tended to increase compared to baseline (*p* = 0.08), and at post-point, it increased significantly compared to baseline (*p* = 0.03) (Fig. [1](#F1){ref-type="fig"}b). At mid-point (*p* = 0.01) and post-point (*p* = 0.001), NK cell activity in the outpatients increased significantly compared to baseline (Fig. [1](#F1){ref-type="fig"}b). The other biomarkers did not change throughout the trial (Table [4](#T4){ref-type="table"}). Febrile frequency in the bedridden inpatients did not change throughout the trial, whereas at the second month in the control inpatients, it increased significantly compared to the first month (*p* = 0.03) (Fig. [2](#F2){ref-type="fig"}). Febrile frequency did not show a condition × time interaction.

Discussion
==========

In this study, we investigated whether supplementation of a combination of glutamine, arginine, leucine, and 11 kinds of vitamins had beneficial effects on the health of older people in poor health. The aging process in humans results in sarcopenia, which involves loss of skeletal muscle mass and function leading to metabolic diseases such as obesity and type 2 diabetes.^([@B36],[@B37])^ To improve body composition, older outpatients in this study were administered a powder containing leucine because it activates muscle protein synthesis. It has been shown that ingestion of 6.7 g of essential amino acids containing 2.75 g of leucine increases muscle protein synthesis (increase of 0.008% per hour) in younger and older people.^([@B30])^ The outpatients in this study were each administered 600 mg of leucine immediately after dinner and before sleeping. Because the outpatients had dinner every evening, it was thought that total leucine intake over a short duration in the evenings was at least above 1.2 g. Extrapolation of these data toward the effect of leucine supplementation with dinner for 8 weeks would theoretically result in almost a 0.3 kg gain in muscle mass. However, an 8-week period of leucine supplementation did not increase lean body mass in the outpatients (Fig. [1](#F1){ref-type="fig"}a). It has been shown that ingestion of 6.7 g of essential amino acids containing 2.75 g of leucine increased muscle protein synthesis, whereas 7.5 g/day of leucine supplementation for 3 months did not induce any changes in the muscle mass and strength of healthy elderly people.^([@B30],[@B38])^ However, it is thought that muscle protein synthesis is influenced by daily total protein or leucine intake. A daily protein intake above 0.85 g protein/kg body weight is adequate for older people.^([@B39])^ It has been shown that muscle mass does not increase in subjects whose habitual protein intake is approximately 78 g/day, even if administered 7.5 g/day of leucine for 3 months.^([@B38])^ The outpatients daily protein intake in this study was above 0.85 g protein/kg body weight. Therefore, we can speculate that the outpatients had adequate daily intake of protein and associated leucine. Moreover, the outpatients also had severe diseases. Therefore, their daily physical activity was low, which may have countered the leucine-induced muscle protein synthesis response even if daily intake of protein was adequate and leucine intake increased muscle protein synthesis. To increase muscle mass of older people in poor health, it might be necessary to increase physical activity and leucine intake associated with more physical activity.

Immune parameters were also evaluated in this study. Of these, NK cell activity, an index of innate immunity, increased in the outpatients and inpatients (Fig. [1](#F1){ref-type="fig"}b). In the immune system, NK cell activity is thought to be one of the important indices for monitoring immunity because innate immunity is the first line of defense against infections. It has been shown that NK cell activity is impaired due to various stressors, such as chronic heart failure^([@B40])^ and high-intensity physical exercise.^([@B41])^ Moreover, it has been understood that NK cell activity is mediated, at least partially, by nitric oxide-mediated pathways.^([@B42],[@B43])^ Therefore, it is thought that arginine has a positive effect on NK cell activity because it is the only biosynthetic substrate for nitric oxide. *In vitro*^([@B42])^ and *in vivo*^([@B4])^ studies have shown that arginine administration enhances NK cell activity. The participants in this study were administered 3 kinds of amino acids. Although the relative efficacy of increased NK cell activity is difficult to estimate, arginine might have been a key factor in this result. The febrile frequency in the control inpatients showed a variation between the first and second halves of the trial, whereas that of the bedridden inpatients was stable throughout (Fig. [2](#F2){ref-type="fig"}). This result implies that the innate immune system of the inpatients who were administered amino acids was stable due to increased NK cell activity.

Glutamine is the most abundant free amino acid in the human body. It is known to be a conditionally essential amino acid because its plasma levels decrease severely when people are critically ill.^([@B12],[@B13])^ Nosocomial infections can cause severe clinical problems in older inpatients. To prevent these infections, restoration of immune and gut-barrier functions is important.^([@B44])^ It has been shown that glutamine supplementation increases lymphocyte count and T-lymphocyte response in surgical patients in addition to improving intestinal immune cell function.^([@B45])^ In this study, glutamine supplementation did not increase leukocyte, lymphocyte, and monocyte counts (Table [4](#T4){ref-type="table"}). Although the participants showed increased NK cell activity, and the febrile frequency of the inpatients was stable, our limited data did not show whether these results were directly or indirectly influenced by glutamine supplementation. Therefore, further research is required to clearly examine the effects of glutamine supplementation on health conditions in older people with poor health.

It has been observed that supplementation with more than 1 g/day of vitamin C improves immunity in healthy adults.^([@B24])^ Supplementation with vitamin E in unhealthy subjects (750 mg/day) and in healthy elderly subjects (800 mg/day) enhance their immunity.^([@B25],[@B46])^ The amount of administered vitamins in this study was smaller than that administered in the previous studies. Although the contribution of individual substrates to the increased NK cell activity was not identifiable, it may have partially influenced NK cell activity. This issue should be resolved in future researches.

In conclusion, this study suggested that dietary supplementation with the amino acids arginine (500 mg/day), glutamine (600 mg/day), leucine (1200 mg/day), and 11 kinds of vitamins for the elderly in poor health increased NK cell activity, regardless of the presence of a primary disease and the amount of the daily nutrient intake. This supplementation may be useful for supporting innate immunity and improving the health of these patients.
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###### 

Health status and prescription drugs

  participant            health status                                                                                   prescription drugs                                                                                                                                                                                trial
  ---------------------- ----------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------
  bedridden inpatients                                                                                                                                                                                                                                                                                                     
  A                      a sequela of brain stem hemorrhage, right gastric cancer                                        ranitidine hydrochloride, polaprezinc, theophylline, carbocysteine, magnesium oxide, pravastatin sodium, clarithromycin                                                                           completed
  B                      after septicemia, a sequela of cerebral infarction                                              polaprezinc, lactobacilli, sodium ferrous citrate, brotizolam                                                                                                                                     completed
  C                      a sequela of cerebral infarction                                                                sodium picosulfate hydrate, amlodipine besylate                                                                                                                                                   completed
  D                      a sequela of cerebral infarction, type 2 diabetes                                               sodium valproate, carbocysteine                                                                                                                                                                   completed
  E                      a sequela of brain hemorrhag                                                                    digoxin, famotidine, brometon, magnesium oxide, famotidine, lactobacilli                                                                                                                          completed
  F                      after acute subdural hematoma                                                                   carbocysteine, ranitidine hydrochloride, lactobacilli                                                                                                                                             dropped out
  G                      type 2 diabetes, a sequela of cerebral infarction, obsolete myocardial infarction               nitroglyerin, tiapride hydrochloride, mosapride citrate                                                                                                                                           completed
  H                      obsolete myocardial infarction, chronic respiratory failure, a sequela of cerebral infarction   aspirin, famotidine, furosemide, magnesium oxide, ticlopidine hydrochloride, amlodipine besylate, spironolactone, pravastatin sodium, sennoside, epinastine hydrochloride, salmeterol xinafoate   dropped out
  I                      general prostration, depression, spondylosis deformans                                          fluticasone propionate, carbocysteine, tiotropium bromide hydrate, clarithromycin, sulpiride                                                                                                      completed
  J                      right nephrosclerosis, left ureter cancer, left brain stem hemorrhage                           aspirin, lactobacilli, zopiclone, sodium picosulfate, proctosedyl                                                                                                                                 completed
  K                      cerebellar infarction, hypertension, aspiration pneumonia, reflux esophagitis                   lactobacilli, omeprazole, mosapride citrate, efonidipine hydrochloride                                                                                                                            dropped out
  L                      type 2 diabetes, pressure sore of sacral region, refractory pneumonia                           enalapril maleate, aspirin, nizatidine                                                                                                                                                            completed
  M                      malignant lymphoma, chronic gastritis                                                           sodium valproate, ursodeoxycholic acid, yokukansan, antibiotic-resistant lactic acid bacteria                                                                                                     completed
  outpatients                                                                                                                                                                                                                                                                                                              
  N                      prostate cancer, a sequela of cerebral infarction, after implant of pacemaker                   amlodipine besylate, ranitidine hydrochloride, troxipide, pravastatin sodium, zopiclone, furosemide, magnesium oxide, allopurinol, digoxin, glybenclamide, aspirin                                dropped out
  O                      angina pectoris, paroxysmal tachycardia, after surgery of colon cancer, atrial extrasystole     tocopherol nicotinate, dipyridamole, isosorbide dinitrate, brotizolam, nitroglyerin, sodium ferrous citrate, zolpidem tartrate                                                                    completed
  P                      left ventlicular hypertrophy, anemia after surgery of gastric cancer, refractory pneumonia      diazepam, fursultiamin, mecobalamin, omeprazole, polaprezinc, brotizolam, itoprode hydrochloride, sennoside                                                                                       completed
  Q                      chronic gastritis, impairment of liver function, hyperlipemia                                   azulene sulfonate sodium, vitamin B compound                                                                                                                                                      dropped out
  R                      hypertension, ventricular extrasystole, overactive bladder non-neurogenic overactive bladder    tamsulosin hydrochloride, hachimijirogan, fexofenadine hydrochloride, mexiletine hydrochloride, valsartan                                                                                         completed
  S                      type 2 diabetes, iron deficiency anemia, diabetic peripheral neuropathy                         mecobalamin, valsartan, epalrestat, cilnidipine, pioglitazone hydrochloride                                                                                                                       completed
  T                      type 2 diabetes, diabetic nephropathy, iron deficiency anemia                                   kalliginogenase, voglibose, fluvastatin sodium, ranitidine hydrochloride, plaunotol, difenidol hydrochloride, disopyramide                                                                        completed
  U                      iron deficiency anemia, hypertension                                                            losartan                                                                                                                                                                                          completed
  V                      cerebral infarction, hepatitis type C, liver cirrhosis, hypertension                            aspirin, quinapril hydrochloride, doxazosin mesilate, enalapril maleate, trichlormethiazide, nifedipine, ranitidine hydrochloride, troxipide, sennoside, loratadine                               completed
  W                      iron deficiency anemia                                                                          Not prescripted                                                                                                                                                                                   completed
  X                      type 2 diabetes, diabetic peripheral neuropathy                                                 glybenclamide, alfacalcidol, ranitidine hydrochloride, flurbiprofen, azulene sulfonate sodium                                                                                                     completed

###### 

Liquid diet composition/pack (2000 kcal/1000 ml)

  ------------------- -------- --------------- ------- ----------------------- -------- ----------------- ----- --------------- ------
  carbohydrate (g)    246      minerals (mg)           vitamins                         amino acids (g)                         
  fat (g)             86       potassium       1496    vitamin A (µg)          1496.3   isoleucine        3.2   arginine        2.1
  sodium (g)          0.5      calcium         1103    vitamin B1 (mg)         4.0      leucine           6.0   glycine         1.2
  dietary fiber (g)   1.7      magnesium       359     vitamin B2 (mg)         4.62     lysine            5.0   alanine         1.9
  water               700 mL   phosphorus      1148    vitamin B6 (mg)         5.04     methionine        1.8   serine          3.7
                               iron            25.0    vitamin B12 (µg)        1.0      cystine           0.2   aspartic acid   4.6
                               zinc            18.90   vitamin C (mg)          349.7    phenylalanine     3.4   glutamate       14.7
                               copper          3.0     vitamin D (µg)          9.98     tyrosine          2.7   proline         7.2
                               manganese       0.16    vitamin E (mg)          18.0     threonine         2.8                   
                               chlorine        998     niacin (mg)             53.9     tryptophan        0.8                   
                               selenium (µg)   89.8    folic acid (µg)         399.0    valine            4.1                   
                                                       pantothenic acid (mg)   25.0     histidine         2.0                   
  ------------------- -------- --------------- ------- ----------------------- -------- ----------------- ----- --------------- ------

###### 

Amino acid and vitamin composition/pack

  amino acid   (mg)   vitamin            (mg)
  ------------ ------ ------------------ -------
  arginine     250    vitamin A          0.45
  glutamine    300    vitamin B1         1.4
  leucine      600    vitamin B2         1.6
                      vitamin B6         2.0
                      vitamin B12        0.004
                      vitamin C          170
                      vitamin D          0.005
                      vitamin E          8.0
                      niacinamide        11.0
                      folic acid         0.4
                      pantothenic acid   5.5

###### 

Hematological and biochemical parameters

                                        Group         baseline        mid-point       post-point
  ------------------------------------- ------------- --------------- --------------- ----------------
  erythrocyte (million/µl)              inpatients    3.97 ± 0.74     4.02 ± 0.63     4.04 ± 0.59
                                        outpatients   3.97 ± 0.25     3.89 ± 0.28     3.87 ± 0.21
  hemoglobin (g/dl)                     inpatients    12.22 ± 2.04    12.37 ± 1.77    12.52 ± 1.53
                                        outpatients   11.92 ± 1.32    11.73 ± 1.48    11.61 ± 1.24
  Ht (%)                                inpatients    38.0 ± 6.2      38.5 ± 5.4      38.8 ± 4.9
                                        outpatients   36.8 ± 3.2      36.8 ± 3.5      36.4 ± 3.0
  platelet (thousand/µl)                inpatients    243.4 ± 42.8    240.6 ± 44.1    248.8 ± 38.0
                                        outpatients   218.1 ± 63.9    209.2 ± 5.87    216.7 ± 70.5
  leukocyte (/µl)                       inpatients    7320 ± 1530     7860 ± 1680     7310 ± 1290
                                        outpatients   5230 ± 1260     5120 ± 1070     4820 ± 870
  basophilic leukocyte (%)              inpatients    0.50 ± 0.37     0.63 ± 0.60     0.67 ± 0.56
                                        outpatients   0.64 ± 0.30     0.50 ± 0.32     0.49 ± 0.36
  neutrophilic leukocyte (%)            inpatients    52.54 ± 8.87    57.72 ± 10.04   54.26 ± 7.63
                                        outpatients   56.76 ± 13.47   56.66 ± 12.52   53.37 ± 12.86
  acidophilic leukocyte (%)             inpatients    6.11 ± 7.32     5.88 ± 7.04     5.97 ± 6.62
                                        outpatients   2.36 ± 1.71     2.07 ± 1.35     2.08 ± 1.44
  lymphocyte (%)                        inpatients    34.30 ± 4.72    28.36 ± 5.66    32.51 ± 5.07
                                        outpatients   33.80 ± 12.88   34.46 ± 10.80   36.62 ± 12.51
  monocyte (%)                          inpatients    6.55 ± 1.95     7.21 ± 2.28     6.59 ± 1.40
                                        outpatients   6.44 ± 1.07     6.32 ± 1.78     7.44 ± 2.64
  total plasma protein (g/dl)           inpatients    6.98 ± 0.58     7.01 ± 0.62     7.07 ± 0.54
                                        outpatients   7.12 ± 0.56     7.13 ± 0.54     7.10 ± 0.44
  albumin (g/dl)                        inpatients    3.58 ± 0.29     3.62 ± 0.31     3.64 ± 0.24
                                        outpatients   4.12 ± 0.23     4.11 ± 0.34     4.14 ± 0.29
  total bilirubin (mg/dl)               inpatients    0.29 ± 0.09     0.35 ± 0.14     0.35 ± 0.15
                                        outpatients   0.61 ± 0.23     0.56 ± 0.13     0.56 ± 0.11
  aspartate aminotransferase (IU/L)     inpatients    28.70 ± 15.05   36.00 ± 23.71   23.20 ± 5.49
                                        outpatients   29.22 ± 18.98   25.44 ± 5.29    27.33 ± 6.56
  alanine aminotransferase (IU/L)       inpatients    20.20 ± 13.81   32.70 ± 28.28   20.70 ± 10.09
                                        outpatients   22.78 ± 21.24   19.11 ± 6.19    20.33 ± 8.03
  leucine aminopeptidase (IU/L)         inpatients    45.00 ± 11.05   47.89 ± 14.15   47.00 ± 12.76
                                        outpatients   38.89 ± 5.23    38.67 ± 4.61    38.89 ± 2.89
  cholinesterase (IU/L)                 inpatients    3772 ± 940      3770 ± 821      3940 ± 836
                                        outpatients   3754 ± 637      3722 ± 816      3798 ± 775
  gamma-glutamyltranspeptidase (IU/L)   inpatients    30.40 ± 23.19   38.30 ± 28.74   35.50 ± 31.87
                                        outpatients   16.89 ± 6.47    16.78 ± 6.94    16.67 ± 4.61
  blood urea nitrogen (mg/dl)           inpatients    21.80 ± 7.97    22.80 ± 9.60    23.10 ± 8.20
                                        outpatients   15.44 ± 3.97    16.22 ± 4.89    16.11 ± 3.37
  serum creatinine (mg/dl)              inpatients    0.63 ± 0.18     0.61 ± 0.15     0.67 ± 0.20
                                        outpatients   0.73 ± 0.18     0.75 ± 0.21     0.76 ± 0.21
  serum amylase (IU/L)                  inpatients    90.90 ± 33.00   85.80 ± 32.58   84.40 ± 31.44
                                        outpatients   97.11 ± 51.61   97.44 ± 45.45   100.33 ± 16.92
  CRP (mg/dl)                           inpatients    1.02 ± 1.79     1.18 ± 1.21     1.38 ± 2.81
                                        outpatients   0.29 ± 0.52     0.06 ± 0.06     0.04 ± 0.04
